Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Predicting response to chemotherapy in patients with Hodgkin's disease or lymphoma high-grade malignant de novo or recurrence.

The non-Hodgkin's lymphoma and high-grade Hodgkin's disease may show resistance to chemotherapy, regardless of their initial extension. The failure of treatment is most often correlated with an incomplete answer or lack of response to chemotherapy as a result chemoresistance. This drug, which may involve the gene MDR1 (multidrug resistance) encoding the protein PGP, can be studied in vivo by MIBI scan. The MIBI is behind a tracer perfusionnel used routinely to explore myocardial perfusion, but it has other characteristics of fixing, which can be used in oncological imaging (fixation by glial tumors of high grade).Prospective Study, which includes conducting a tomoscintigraphie 30 minutes after injection of 20 mCi of 99mTc-MIBI in initial stock or relapse of high-grade lymphoma and Hodgkin's disease any stage (I-IV). Fixing the MIBI is compared with morphological abnormalities detected by CT and the setting of lesions by 18FDG. Patients will be treated in a traditional way, without changes in treatment protocols used in routine. Patients with a negative MIBI scan, will be watched with particular attention in order to detect insufficient response to chemotherapy. The only change, the care of patients, only for the achievement of an initial consideration of non-invasive imaging, further, which is the tomoscintigraphie the MIBI. Of the tumor samples, will be evaluated by immunohistochemistry, the expression of PGP and the MRP1 (two proteins associated with the drug). On blood, may be carried out genotyping of MDR1, MRP1 and MRP2 to the patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

NCT06744075

B-cell Lymphoma Hodgkin Lymphoma

ACTIVE_NOT_RECRUITING NA

Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma

NCT02815137

Classical Hodgkin Lymphoma

COMPLETED NA

Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma

NCT05422521

Refractory or Relapsed Non-Hodgkin's Lymphoma

RECRUITING NA

Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas

NCT00685997

Malignant Lymphoma Hodgkin's Disease Non-Hodgkin's Lymphoma

COMPLETED

Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

NCT04298619

Hodgkin Lymphoma High Risk Relapse

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin's Disease Malignant Lymphomas High Grade Chemoresistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TEP au MIBI

Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* initial Attainment: High-grade NHL or Hodgkin's disease all stages:I, II, III et IV.
* Relapse: High-grade NHL or Hodgkin's disease relapse in all stages:I, II, III et IV.
* Patients recruited by the Network of clinical hematology du Limousin
* Patients older than 18 years with or without brain damage

Exclusion Criteria

* Pregnant women or nursing mothers or without effective contraception
* Patients without coverage by social security
* Patients who started steroids referred to antitumor

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No